• The coronavirus mutates more slowly than the flu - which means a vaccine will likely be effective long-term

    14 days ago - By Business Insider

    Scientists around the world are racing to develop a vaccine for the new coronavirus , which has infected more than 467,000 people.
    All viruses, including this one, mutate over time. As they replicate, minute errors are introduced into their genetic codes.
    For some viruses, like the flu, these errors collect more quickly over time and can change how the virus behaves - necessitating a new vaccine every year.
    The new coronavirus, however, seems to mutate slowly, experts say. This means its vaccine would likely be effective long-term, much like a measles vaccine.
    Visit Business Insider's...
    Read more ...

     

  • US companies are still betting on Chinese consumers, despite coronavirus impact

    US companies are still betting on Chinese consumers, despite coronavirus impact

    14 days ago - By CNBC

    The American Chamber of Commerce in China's survey of members in March found that the consumer sector had one of the largest revenue disruptions, but had the highest proportion of businesses saying they would stick to their investment plans.
    Read more ...

     

  • Gilead made a remarkable request of the FDA in regard to its coronavirus drug

    14 days ago - By Fortune

    Happy Wednesday, readers.
    Remdesivir, the experimental COVID-19 treatment from Gilead , has been one of the drugs thought to have the most potential to treat the novel coronavirus. It's already been deployed in the U.S. and multiple other countries as this pandemic spreads.
    During, say, any other time in the history of the biotech industry, that's an advantage a corporation would likely hold onto. Clearly, these aren't normal times.
    Read more ...

     

  • How one company is fast-tracking development of potential plasma-based treatments for the coronavirus

    14 days ago - By Tech Crunch

    Medical biotech company Emergent BioSolutions is one of the many health industry players turning its efforts towards addressing the current global coronavirus pandemic. Their work includes a two-pronged effort to pursue plasma-based treatments that could help lessen the impact of COVID-19 on health care systems, with a fast-tracked development timeline that could see human clinical trials start as soon as this summer.
    The company is simultaneously working on two different therapeutic approaches, including one that uses plasma (a liquid that is the majority component of blood) sourced from...
    Read more ...